Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in reducing the incidence of lung TB disease in HIV-negative adults, already infected with...
Social Reponsiveness
Established in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) was presented with the University of Cape Town’s (UCT) 2018 Social Responsiveness Award at the Faculty of Health Sciences graduation ceremony on Saturday, 13 April 2019
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...


Sunday, 26 January 2020
21 January 2020: Latest Research: Headway made towards biosignatures for tuberculosis incipient

Professor Tom Scriba and Dr Simon Mendelsohn have published a journal article titled: "Making headway towards biosgnatures for incipient tuberculosis" appearing in the Lancet Respiratory Medicine. 

Publication Date:
Tue, 21 Jan 2020 - 15:00
2 December 2019: EDCTP funded clinical trial testing new tuberculosis vaccine initiates vaccinations

The Prevention of Recurrence (POR) Consortium has been awarded a substantial grant from the European & Developing Countries Clinical Trial Partnership (EDCTP) which will support a clinical trial in South Africa and Tanzania of a new and promising tuberculosis (TB) vaccine candidate H56:IC31, developed by the Statens Serum Institute (SSI). 

Publication Date:
Wed, 18 Dec 2019 - 08:45
22 November 2019 Research Preferred product characteristics for therapeutive vaccines

Professor Mark Hatherill has co-authored a journal article titled: "Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organisation consultations" appearing in the Vaccine journal.

Publication Date:
Fri, 22 Nov 2019 - 13:45
14 November 2019 Research: Book Chapter: Diagnosing childhood tuberculosis during a vaccine trial in South Africa.

Dr Michèle Tameris, has co-authored a book chapter titled "Between representing and intervening: Diagnosing childhood tuberculosis during a vaccine trial in South Africa".

Publication Date:
Thu, 14 Nov 2019 - 22:45